Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib plus lenvatinib versus regorafenib in lenvatinib-resistant EGFR-positive advanced hepatocellular carcinoma
ChiCTR2200062854Phase 2Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gefitinib, lenvatinib and regorafenib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Huashan Hospital. Primary endpoints: Tumor size, Alpha-fetoprotein and 2 more. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200062854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062854.